Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIDA
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
AIDA (1-aminoindan-1,5-dicarboxylic acid) is a synthetic compound that acts as a selective antagonist of the metabotropic glutamate receptor subtype 1 (mGluR1). It is primarily used in research settings to study the role of mGluR1 in neurophysiology and neuropharmacology. By blocking mGluR1 activity, AIDA helps elucidate the function of this receptor in synaptic transmission and neurological disorders. There are no known approved therapeutic indications for AIDA as a pharmaceutical drug; its use is limited to experimental and laboratory research[4].
- Other names
- 1-Aminoindan-1,5-dicarboxylic acid(RS)-1-Aminoindan-1,5-dicarboxylic acid1-aminoindane-1,5-dicarboxylic acid
02
Targets
GRM5 (Metabotropic glutamate receptor 5)GRM1 (Metabotropic glutamate receptor 1)
Beyond the preview
Go deeper on AIDA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIDA.